NTRK Alterations in Pediatric High-Risk Malignancies Identified Through European Clinical Sequencing Programs Constitute Promising Drug Targets.
Elke PfaffTiphaine Adam de BeaumaisAntonin MarchaisCornelis M van TilburgMirjam Blattner-JohnsonUta DirksenIngrid ÖraDidier FrappazGudrun SchleiermacherStefan M PfisterOlaf WittDavid T W JonesGilles VassalPublished in: JCO precision oncology (2022)